Login to Your Account

Takeda buys cell therapy firm Tigenix, inks eurodegenerative deal with Denali

By Nuala Moran
Staff Writer

Friday, January 5, 2018

LONDON – Takeda Pharmaceutical Co. Ltd. is to acquire cell therapy specialist Tigenix NV in a deal valued at €520 million, giving the Japanese pharma full ownership of Alofisel, an off-the-shelf allogeneic therapy for anal fistulas that was recommended for European marketing approval in December.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription